Nature Reviews Drug Discovery

Nature Reviews Drug Discovery is a review journal with an emphasis on drug discovery and development. With an impact factor of 28.712 in 2010 it is the leading journal in pharmacology/pharmacy and biotechnology/applied microbiology areas. The reviews are commissioned to leaders in the their specialties (non-commissioned review submissions are discouraged), but are also peer-reviewed after submission. The reviews are supplemented with glossary explanations for non-specialist readers and illustrated with figures drawn by Nature's in-house art editors. Besides reviews, the journal accepts peer-reviewed analysis articles based on existing datasets (e.g. metaanalysis), progress articles that focus on outstanding issues, and perspective articles—typically opinions or historical pieces.

Publisher
Nature Publishing Group
Country
international
Impact factor
29.008 (2011)

Some content from Wikipedia, licensed under CC BY-SA

Medications

New research predicts market share for drug makers

Lagging behind in launching new medicines means a much smaller market share for pharmaceutical companies—even if they spend just as much on advertising, according to new research from Duke University's Fuqua School of Business.

Neuroscience

How to improve multiple sclerosis therapy

Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase. Many patients, however, develop progressive MS at a later stage, with disability becoming ...

Medications

Drug research and development more efficient than expected

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Alzheimer's disease & dementia

Preventive treatment for Alzheimer's and Parkinson's disease

A diagnosis of Alzheimer's disease is devastating for those affected, as there is still no cure for this type of dementia. One hundred years after Alois Alzheimer first described it, we neither have a drug for it, nor do ...

Medications

Characteristics of international drug regulatory regimes

The regulatory requirements for the approval of new drugs vary greatly internationally in regards to the resources allocated to the authorities, the evaluation periods for approval and the fees for the pharmaceutical companies. ...

Alzheimer's disease & dementia

Potential Alzheimer's drug prevents abnormal blood clots in the brain

Without a steady supply of blood, neurons can't work. That's why one of the culprits behind Alzheimer's disease is believed to be the persistent blood clots that often form in the brains of Alzheimer's patients, contributing ...

page 1 from 2